Related Experiment Video
Updated: Aug 17, 2026
Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Goreisan suppresses cardiac remodeling and dysfunction in a new mouse model with diabetic cardiomyopathy
Masafumi Funamoto1, Shunji Hirose2, Mizuho Yamamoto1
1Department of Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Tokushima, Japan.
Background:
The global increase in diabetes, driven by aging populations and lifestyle changes, has led to an increase in the incidence of diabetic cardiomyopathy (DCM). DCM is characterized by metabolic abnormalities, oxidative stress, and inflammation, leading to cardiac remodeling and dysfunction. Goreisan (GRS), a traditional Japanese Kampo medicine, is commonly used to treat fluid control such as edema, due to its diuretic effect. In this study, we examined the effects of GRS on DCM.
Methods:
We first established a new mouse model of DCM and then evaluated the effects of GRS on DCM using a recently developed model.
Results:
The DCM mouse model developed cardiac hypertrophy, fibrosis, and dysfunction by nine weeks, which was ameliorated by GRS administration. GRS suppressed apoptosis and protein degradation by inhibiting Akt dephosphorylation and oxidative stress in DCM mice. In contrast, no differences in inflammatory cytokine levels were observed, regardless of GRS administration.
Conclusion:
GRS has potential efficacy in preventing DCM onset and development.
Insights
Goreisan (GRS) may prevent diabetic cardiomyopathy (DCM) by inhibiting cardiac remodeling and dysfunction. This traditional medicine shows potential in treating DCM, a growing concern linked to diabetes.
Area of Science:
- Cardiology
- Pharmacology
- Endocrinology
Background:
- Diabetic cardiomyopathy (DCM) incidence is rising globally due to diabetes.
- DCM involves metabolic issues, oxidative stress, and inflammation, causing heart remodeling and dysfunction.
- Goreisan (GRS), a Kampo medicine, is known for its diuretic properties and use in fluid management.
Purpose of the Study:
- To investigate the therapeutic effects of Goreisan (GRS) on diabetic cardiomyopathy (DCM).
Main Methods:
- A novel mouse model for DCM was established.
- The efficacy of GRS in treating DCM was evaluated using this established model.
Main Results:
- GRS administration ameliorated cardiac hypertrophy, fibrosis, and dysfunction in the DCM mouse model.
- GRS inhibited Akt dephosphorylation and oxidative stress, suppressing apoptosis and protein degradation.
- GRS did not significantly alter inflammatory cytokine levels in DCM mice.
Conclusions:
- Goreisan (GRS) demonstrates potential in preventing the onset and progression of diabetic cardiomyopathy.
- GRS may offer a novel therapeutic strategy for managing DCM.
- Further research into GRS for DCM is warranted.
